Exploring Policy Options for Establishing Cannabidiol Safety Surveillance

Since the passage of the Agriculture Improvement Act of 2018, consumers have experienced increased access to products containing cannabidiol (CBD); however, there remains a lack of information about the safety of CBD. Establishing a CBD safety surveillance system would allow regulators to obtain a better understanding of the risks of CBD, and would enable them to quickly identify and respond to emerging public health threats related to CBD. This private workshop, convened under a cooperative agreement between the Robert J. Margolis, MD, Center for Health Policy at Duke University and the U.S. Food and Drug Administration (FDA), will explore opportunities to develop systems and approaches to gain better insight into the safety of CBD with the goal of informing policymakers and public health professionals. Key topics for discussion include:
•    Exploring existing CBD safety surveillance efforts;
•    Identifying key data and methodological challenges when studying CBD safety;
•    Considering which data sources could be used to assess CBD safety; and,
•    Identifying potential policy approaches and next steps to improve understanding of CBD safety.

Funding for this meeting was made possible in part by a grant from the U.S. Food and Drug Administration. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the U.S. Food and Drug Administration nor does mention of trade names, commercial practices, or organizations imply endorsements.